(Q29038941)

27 March 2017

main subject

diagnosis

0 references

visceral leishmaniasis

1 reference

0 references

0 references

Shyam Sundar

1 reference

27 March 2017

Asrat Hailu

1 reference

27 March 2017

Rosanna W. Peeling

1 reference

27 March 2017

Hashim Ghalib

1 reference

27 March 2017

Suman Rijal

series ordinal

1 reference

27 March 2017

Jorge Alvar

series ordinal

1 reference

27 March 2017

language of work or name

English

0 references

publication date

November 2007

1 reference

Nature Reviews Microbiology

27 March 2017

published in

1 reference

27 March 2017

volume

1 reference

27 March 2017

issue

1 reference

27 March 2017

page(s)

S7-S16

1 reference

Clinical spectrum of Leishmaniasis

27 March 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Epidemiology of visceral leishmaniasis in northeast Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

New perspectives on a subclinical form of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Malnutrition as a risk factor for severe visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Risk factors for kala-azar in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

rK39: A Cloned Antigen of Leishmania chagasi that Predicts Active Visceral Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Visceral leishmaniasis treatment, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The strange case of Leishmania chagasi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Post-kala-azar dermal leishmaniasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmaniasis: current situation and new perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Unseen Kala-azar deaths in south Sudan (1999-2002).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Visceral leishmaniasis control: a public health perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The increase in risk factors for leishmaniasis worldwide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmaniasis and poverty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The economic burden of visceral leishmaniasis for households in Nepal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Kala-azar in displaced people from southern Sudan: epidemiological, clinical and therapeutic findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmania-host-cell interaction: complexities and alternative views.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A prospective sero-epidemiological study of visceral leishmaniasis in Baringo district, Rift Valley Province, Kenya

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Visceral leishmaniasis in Ethiopia. IV. Prevalence, incidence and relation of infection to disease in an endemic area.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A leishmanin skin test survey in the human population of l'Alacantí region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Kala-azar as an AIDS-related opportunistic infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Genetics and visceral leishmaniasis in the Sudan: seeking a link

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmaniasis: new approaches to disease control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Canine leishmaniasis: novel strategies for control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Detection of high rates of in-village transmission of Leishmania donovani in eastern Sudan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Evaluation of a mass distribution programme for fine-mesh impregnated bednets against visceral leishmaniasis in eastern Sudan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmania braziliensis braziliensis isolated from Akodon arviculoides captured in Caratinga, Minas Gerais, Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Comparative merits of sternum, spleen and liver punctures in the study of human visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Utility of lymph node aspiration in the diagnosis of visceral leishmaniasis in Sudan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Molecular diagnosis of leishmaniasis: current status and future applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Immunologic tests in patients after clinical cure of visceral leishmaniasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Pre- and post-treatment antibody levels in visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Epidemiological study of kala-azar by direct agglutination test in two rural communities of eastern Nepal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

An Enzyme-Linked Immunosorbent Assay (Elisa) for Field Diagnosis of Visceral Leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Diagnosis of visceral leishmaniasis: comparative potential of amastigote antigen, recombinant antigen and PCR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A simple and economical direct agglutination test for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Multi-centre evaluation of repeatability and reproducibility of the direct agglutination test for visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A fast agglutination screening test (FAST) for the detection of anti-Leishmania antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Field evaluation of a fast anti-Leishmania antibody detection assay in Ethiopia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Application of direct agglutination test (DAT) and fast agglutination screening test (FAST) for sero-diagnosis of visceral leishmaniasis in endemic area of Minas Gerais, Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Antigenuria in visceral leishmaniasis: detection and partial characterisation of a carbohydrate antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The world's most neglected diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Liposomal amphotericin B for the treatment of visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Miltefosine to treat leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Socio-economics of visceral leishmaniasis in Bihar (India)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Treatment options for visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Injectable paromomycin for Visceral leishmaniasis in India

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A policy for leishmaniasis with respect to the prevention and control of drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmania vaccines: progress and problems.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The genome of the kinetoplastid parasite, Leishmania major

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Cutaneous leishmaniasis: The prospects for a killed vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Development of a leishmaniasis vaccine: the importance of MPL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

HIV--Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The biological diagnosis of leishmaniasis in HIV-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The performance of direct agglutination tests (DAT) in the diagnosis of visceral leishmaniasis among Ethiopian patients with HIV co-infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Leishmaniasis: current status of vaccine development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

inferred from DOI database lookup

7 January 2021

based on heuristic

Kala-azar in a high transmission focus: an ethnic and geographic dimension

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

inferred from DOI database lookup

7 January 2021

based on heuristic

Application of an improved method for the recombinant k 39 enzyme-linked immunosorbent assay to detect visceral leishmaniasis disease and infection in Bangladesh

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1748

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRMICRO1748

2 references

27 March 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1006874978

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

17938629

1 reference

Consolidated OpenCitations Corpus – April 2017